Protillion Biosciences
Carlsbad, US · 2 known investors
Protillion Biosciences develops platform technology for antibody engineering and drug discovery.
Founders & leadership
CL

Curtis LaytoninCEO/Co-Founder
DW.png)
.png)
David WaltinCo-Founder
WG

Will GreenleafinCo-Founder
RH.png)
.png)
Robert HollingsworthinChief Scientific Officer
SK
Sean KendallDirector
MF
Malek FahamDirector
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$19MraisedDec 2022 · 9 investors · OtherRule 506(b)
▶$19MraisedDec 2022 · 9 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Sean KendallDirector
- David WaltDirector
- Malek FahamDirector
- Curtis LaytonExecutive Officer, Director
- Offering amount
- $20.7M
- Amount sold
- $19M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Historic Biotech IPO, Merck, Protillion’s AI Deal, Testing a Lassa–Rabies Vaccinegenengnews.com · 2026
- CollectiveMinds LLC Places Robert Hollingsworth, PhD as Chief Scientific Officer of Protillion Biosciencesfinance.yahoo.com · 2026
- Protillion Biosciences Raises $18 Million Series A Financing Led by ARCH Venture Partners and Illumina Ventures - BioSpacebiospace.com · 2022
- Protillion Biosciences - Tech Company Profile - Gaebler.com Venture Capital Databasegaebler.com
- Protillion Biosciences 12/19/2022 Capital Raise - Gaebler.com Venture Capital Databasegaebler.com